A 3-(1-methylpyrrolidin-2-yl)pyridine in which the chiral centre has S-configuration. The naturally occurring and most active enantiomer of nicotine, isolated from Nicotiana tabacum.
Chemical ID:
MESH:D009538
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
1-(5-azido-6-chloropyridin-3-ylmethyl)-2-nitroiminoimidazolidine inhibits the reaction [Nicotine analog binds to [CHRNA4 protein co-treated with CHRNB2 protein]]; [Dihydro-beta-Erythroidine binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] which results in decreased susceptibility to Nicotine; [Nicotine co-treated with Benzo(a)pyrene] results in decreased expression of [CHRNA4 protein binds to CHRNB2 protein]; Bungarotoxins inhibits the reaction [Nicotine results in increased expression of CHRNA4 protein]; Cocaine inhibits the reaction [Nicotine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Dihydro-beta-Erythroidine analog inhibits the reaction [Nicotine results in increased expression of CHRNA4 mRNA]; imidacloprid analog inhibits the reaction [Nicotine analog binds to [CHRNA4 protein co-treated with CHRNB2 protein]]; N-(5-azido-6-chloropyridin-3-ylmethyl)-N'-methyl-N''-nitroguanidine inhibits the reaction [Nicotine analog binds to [CHRNA4 protein co-treated with CHRNB2 protein]]; Nicotine analog binds to [CHRNA4 protein co-treated with CHRNB2 protein]; Nicotine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; Nicotine results in increased expression of [CHRNA4 protein binds to CHRNB2 protein]
CHRNA4 gene polymorphism affects the susceptibility to Nicotine; CHRNA4 protein affects the susceptibility to Nicotine; CHRNA4 protein mutant form affects the susceptibility to Nicotine
[N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide co-treated with Nicotine] inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased expression of CHRNA4 protein]; cytisine inhibits the reaction [Nicotine results in increased expression of CHRNA4 protein]; Hexamethonium inhibits the reaction [Nicotine results in increased expression of CHRNA4 protein]; Nicotine binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CHRNA4 protein]; Tubocurarine inhibits the reaction [Nicotine results in increased expression of CHRNA4 protein]
[CHRNA4 protein binds to CHRNB2 protein] which results in increased susceptibility to Nicotine; [Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; [Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; [Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein]; Nicotine inhibits the reaction [cytisine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Nicotine inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Nicotine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; Nicotine results in increased activity of [CHRNB4 protein binds to CHRNA4 protein]; Rosiglitazone inhibits the reaction [Nicotine results in increased expression of CHRNA4 protein]